What is oral Wegovy and when was it approved?

Oral Wegovy is the first GLP-1 weight loss pill approved by the FDA on December 22, 2025. The drug contains semaglutide — the same active ingredient as injectable Wegovy and Ozempic — but in a convenient daily oral tablet form. It launched at over 70,000 US pharmacies in January 2026, marking a historic shift in obesity treatment accessibility. The oral formulation eliminates the need for weekly injections that many patients found inconvenient or uncomfortable.

How effective is oral Wegovy for weight loss?

In the Phase III OASIS 4 clinical trial, oral Wegovy achieved an average 16.6% body weight reduction over 64 weeks. This efficacy is somewhat lower than injectable Wegovy, which achieves approximately 15-17% weight loss in comparable timeframes when accounting for dosing differences. However, the oral formulation provides meaningful weight loss for most patients combined with lifestyle changes. Users also reported significant improvements in blood pressure, blood sugar, and cardiovascular risk markers.

How much does oral Wegovy cost?

The cash price for oral Wegovy ranges from $149 to $299 per month depending on pharmacy and dosage, compared to over $1,300 per month for weekly injectable Wegovy. With insurance coverage, costs can drop as low as $25 per month for eligible patients. GoodRx offers discount programs, and Novo Nordisk provides savings cards for qualifying patients. The dramatically lower price point relative to injections could make GLP-1 treatment accessible to tens of millions of additional patients who could not previously afford treatment.

Where can patients get oral Wegovy?

Oral Wegovy is available at over 70,000 US pharmacies including CVS, Walgreens, Rite Aid, and Costco. Telehealth providers including Ro, LifeMD, and WeightWatchers Clinic offer prescriptions and pharmacy delivery. GoodRx enables price comparison across pharmacies. The wide availability represents a dramatic contrast to injectable Wegovy, which faced persistent shortages since launch. Novo Nordisk planned production capacity to avoid the supply problems that plagued injectable versions.

Is oral Wegovy better than injectable Wegovy?

Both formulations contain semaglutide but differ in convenience, efficacy, and cost. Injectable Wegovy delivered weekly achieves slightly higher peak efficacy at comparable doses, but oral Wegovy offers daily dosing that some patients find easier to maintain as a routine. The oral version is far cheaper and more convenient. For patients who struggled with injections or who needed a lower-cost option, oral Wegovy represents a superior choice. For maximum weight loss, injectable forms still hold a small efficacy advantage.

Oral Wegovy — FDA-approved GLP-1 weight loss pill

/// Health Trend 2026

Oral Wegovy: The $149/Month Weight Loss Pill That Could Replace GLP-1 Injections

Published: March 18, 2026

FDA approved oral Wegovy on December 22, 2025, launching at 70,000+ US pharmacies in January 2026. At just $149–$299/month with 16.6% average weight loss, this is a revolution in obesity treatment.

FDA Approved

Dec 22, 2025

Avg Weight Loss

16.6%

Price/month

$149+

Pharmacies

70,000+

SCROLL DOWN

02 / KEY STATISTICS

Numbers That Are Changing Obesity Treatment

In the OASIS 4 Phase III trial, oral Wegovy achieved an average weight loss of 16.6% over 64 weeks — surpassing nearly every previously approved weight loss medication. This is a turning point in treating obesity in adults.

0.0%

Average weight loss

OASIS 4 trial

$0/mo

Starting cash price

vs $1,000+ for injections

US pharmacies

Available January 2026

0 wks

OASIS 4 Phase III

Trial duration

03 / HOW IT WORKS

How Does Semaglutide Work?

Semaglutide is a GLP-1 receptor agonist (glucagon-like peptide-1). When taken as a pill, it mimics a natural gut hormone that regulates blood sugar, reduces hunger signals, and promotes longer-lasting satiety.

◎

Mimics Natural GLP-1

Semaglutide binds to GLP-1 receptors in the brain, pancreas, and gut, activating the body's natural blood sugar control and appetite regulation mechanisms.

◐

Slows Gastric Emptying

The medication slows how quickly the stomach empties into the small intestine, creating prolonged fullness after meals and reducing total calorie intake.

◑

Signals Brain Satiety

GLP-1 receptors in the brain's hypothalamus receive satiety signals from semaglutide, reducing appetite and cravings for high-calorie foods.

◒

Stabilizes Blood Sugar

Semaglutide stimulates the pancreas to release insulin when blood sugar rises, while suppressing glucagon, helping stabilize post-meal blood glucose levels.

GLP-1 oral weight loss pills — next-generation pharmaceutical

Photo: CNBC — Weight loss pills pharmaceutical — obesity treatment revolution 2026

04 / COMPARISON

Oral Pill vs. Injection: How Do They Compare?

Both formulations contain semaglutide but differ in convenience, cost, and efficacy. Here is a side-by-side comparison to help you choose the option that fits your lifestyle and budget.

FEATURE

ORAL PILL

INJECTION

Administration

Daily oral pill

Weekly injection

Cash price/month

$149–$299

$1,000+

Avg. weight loss

16.6%

~15%

Trial duration

64 weeks (OASIS 4)

68 weeks (STEP 1)

Availability

70,000+ pharmacies

Widely prescribed

With insurance

As low as $25/month

$0–$25/month

* Data from OASIS 4 and STEP 1 trials. Individual results may vary.

05 / WHERE TO GET IT

Where Can You Get Oral Wegovy?

Since January 2026, oral Wegovy has been widely available at 70,000+ pharmacies and telehealth providers across the US. You need a prescription from a doctor or through a telemedicine service.

CVS Pharmacy

Pharmacy

Available at thousands of CVS locations nationwide. Supports insurance and discount programs.

Costco Pharmacy

Pharmacy

Competitive pricing at Costco Pharmacy, especially suitable for Costco members.

Ro

Telehealth

Telehealth platform providing online prescriptions and home delivery. Easy access.

LifeMD

Telehealth

Telemedicine service with obesity specialists, consultation, and treatment monitoring.

GoodRx

Drug discount

GoodRx coupons significantly reduce costs at participating pharmacies across the US.

Weight Watchers

Weight loss program

Weight Watchers integrates oral Wegovy into its comprehensive weight management program.

06 / COMPETITION

Eli Lilly Is Catching Up

Eli Lilly, maker of injectable Mounjaro and Zepbound, is developing orforglipron — an oral GLP-1 pill that directly competes with oral Wegovy. The race between these two pharmaceutical giants could reshape the global obesity treatment market.

2021

FDA Approves Injectable Wegovy

Novo Nordisk receives FDA approval for Wegovy (semaglutide 2.4mg) as a weekly subcutaneous injection.

2023

OASIS 4 Phase III Trial Begins

Novo Nordisk launches the Phase III clinical trial for oral semaglutide pills (OASIS 4).

December 22, 2025

FDA Approves Oral Wegovy

FDA officially approves oral Wegovy — the first GLP-1 pill for weight loss in adults.

January 2026

Commercial Launch

Oral Wegovy becomes available at 70,000+ US pharmacies including CVS, Costco, and telehealth providers.

2026 (expected)

Eli Lilly FDA Submission

Eli Lilly expected to submit FDA approval for orforglipron after completing Phase III trials.

Market Implications

If Eli Lilly's orforglipron receives FDA approval in 2026, direct competition is expected to drive down prices and expand access to obesity treatment for millions of untreated Americans.

$100B+

GLP-1 Market 2030

42%

Obese Americans

90%

Untreated patients

07 / IMAGES

Healthcare in the GLP-1 Era

Photo: NPR — Obesity treatment healthcare — GLP-1 drug access in 2026

▸ An oral GLP-1 pill could help millions avoid weekly injections -- saving ~$1,000/month vs injectable Wegovy without insurance

References

09 / FAQ